<DOC>
	<DOCNO>NCT00534378</DOCNO>
	<brief_summary>Purpose study determine midazolam 's safety dose-linearity deliver intramuscularly via autoinjector . The proposed initial treatment dosage seizure induce exposure nerve agent .</brief_summary>
	<brief_title>Phase I Trail Intramuscular Administration Midazolam Using An Autoinjector</brief_title>
	<detailed_description>The investigational drug product evaluate study Midazolam Autoinjector . This system compose autoinjector fill drug product midazolam EP . The study drug administer IM anterior thigh use preloaded autoinjector . This method administration select method use later clinical trial market product . The autoinjector preloaded midazolam 5 mg 10 mg total volume 1 2 mL . Healthy subject assign one six target dosage group ( 0.10 , 0.18 , 0.25 , 0.33 , 0.40 , 0.49 mg/kg ) , base weight , receive necessary combination fix 5 10 mg dos provide assign target dose .</detailed_description>
	<mesh_term>Seizures</mesh_term>
	<mesh_term>Midazolam</mesh_term>
	<criteria>Generally health adult Physically fit Body Mass Index &gt; / 19 &lt; / 26 body weight 55 85 Kg Have adequate venous access sufficient upper leg muscle tissue Have specify laboratory value Have negative assay HIV1 , HIV2 , HbsAg If femal child bear potential , must pregnant breast feeding , plan become pregnant th eduration study . She must negative blood serum pregnancy test within 21 day treatment , negative urine pregnancy test prior dose . Females childbearing potential use adequate contraception . Willing refrain donate blood 8 week compeletion study . Participated pharmacokinetic study clinical study currently within last 30 day donate &gt; 480mL blood within last 8 week . History presence significant cardiovascular , hepatic , renal , hematologic , gastrointestingal , endocrine , immunologic , dermatologic , neurologic , psychiatric disease could potentially impact safety subject metabolism drug . Be take medication ttreat chronic medical condition Have ongoing drug abuse/dependence ( include alcohol ) ; history treatment alcohol drug abuse History allergic untoward reaction benzodiazepine psychotropic agent Currently suffer frm acute chronic pulmonary disease Clinically relevant abnormal history , physical finding , ECG , laboratory value prestudy screen assessment could interfere objective study safety subject . Pregnant nursing History glaucoma Positive urine test drug abuse Have active malignancy history metastatic hematologic malignancy exception melanoma situ basal squamous cell carcnoma skin Subjects positive test hepatitis B , hepatitis C , syphilis , HIV1 HIV2 Subjects whoe ECG reveals PR interval &gt; / 190 msec Subjects refrain take OTC preparation , herbal remedy , and/or nutritional supplement take within 7 day prior study drug drug administration . Subjects use medically recognize mean birth control Subjects prior history seizure related condition</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>54 Years</maximum_age>
	<verification_date>September 2007</verification_date>
	<keyword>Nerve agent</keyword>
	<keyword>Midazolam</keyword>
	<keyword>Seizures</keyword>
	<keyword>Severe recurrent convulsive seizure induce nerve agent exposure</keyword>
</DOC>